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b-D-Glucan kinetics for the assessment of
treatment response in Pneumocystis jirovecii
pneumonia
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Abstract
Serum (1ﬁ3)-b-D-Glucan (BG) is a biomarker for Pneumocystis
jirovecii pneumonia (PJP). However, information concerning its
usefulness for monitoring the clinical course is lacking. We con-
ducted a retrospective study to investigate whether consecutive
BG-measurements can be used to assess treatment response in
PJP. Analysis of sera from 18 patients during PJP therapy shows
that decreasing BG-levels strongly correlate with a favourable
clinical course. In contrast, increasing BG-levels were associated
with treatment failure or fatal outcome is only 44% of patients.
As a consequence, BG-kinetics might be used to conﬁrm treat-
ment success but seem to be of limited value for the identiﬁca-
tion of treatment failure.
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Early detection and effective therapy is vital in reducing mor-
tality resulting from Pneumocystis jirovecii pneumonia (PJP).
Resistance to ﬁrst-line therapy exists, and because of the
inability to grow the fungus in vitro, there are currently no
reliable methods for the assessment of P. jirovecii antimicro-
bial sensitivity [1,2]. Thus, except for clinical presentation,
improvement of radiological ﬁndings, and non-speciﬁc param-
eters such as the arterial partial pressure of oxygen or lac-
tate dehydrogenase (LDH) levels, no objective tests for
monitoring of treatment efﬁciency exist.
(1–3)-b-D-Glucan (BG) is a cell wall component of P. ji-
rovecii and of various other fungi. BG is released into the
serum during the course of an invasive infection. Emerging
data from recent years have pointed to serum BG measure-
ment as a promising new tool for the diagnosis of PJP [3–5].
However, results concerning its usefulness for following the
patient’s clinical course are missing.
To investigate whether consecutive serum BG measure-
ments can be used to assess treatment response, we retro-
spectively examined all patients presenting at our hospital
between January 2003 and July 2010 with conﬁrmed PJP and
for whom ﬁve or more sera during follow-up were available.
Conﬁrmed PJP required the identiﬁcation of P. jirovecii by im-
munostaining (DETECT IF test; Axis Shield Diagnostics Lim-
ited, Dundee, UK) and/or detection of P. jirovecii DNA by
PCR of bronchoalveolar lavage ﬂuid (BALF), as well as a typi-
cal clinical presentation. P. jirovecii touchdown PCR was per-
formed as previously described [6]. All ampliﬁcation
products were sequenced and conﬁrmed to be parts of the
P. jirovecii mitochondrial large-subunit rRNA gene. Clinical
presentation was considered to be typical if pulmonary inﬁl-
trates compatible with PJP were present and if at least four
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FIG. 1. (1–3)-b-D-Glucan (BG) courses of BG kinetics groups 1 and 2. (a, b) BG kinetics of two patients with mild Pneumocystis jirovecii pneumo-
nia (PJP) and good treatment response. BG levels showed a continuous decrease that reﬂected clinical improvement. Cessation of supportive
oxygen therapy is equivalent to blood gases becoming almost normal. The change of PJP therapy in (b) took place because of trimethoprim–
sulphamethoxazole (SXT)-induced exanthema. (c) Patient with an early increase in BG levels that would have implied treatment failure. However,
the patient responded well to trimethoprim–sulphamethoxazole therapy. (d) Patient with a fatal outcome showing a late increase in BG levels.
While BG levels were rising, the number of P. jirovecii cysts in repeated bronchoalveolar lavage ﬂuid was decreasing, questioning a correlation
between fatal outcome and P. jirovecii-associated BG increase. Clinda/Prima, clindamycin–primaquine; CVVHD, continuous venovenous haemodial-
ysis; LDH, lactate dehydrogenase; Stop O2, cessation of supportive oxygen therapy; PJ-IFT, P. jirovecii immunoﬂuorescence staining.
FIG. 2. (1–3)-b-D-glucan (BG) courses of BG kinetics group 3. (a) BG kinetics of a patient with possible treatment failure. Initially, the patient’s
response to trimethoprim–sulphamethoxazole (SXT) therapy was accompanied by decreasing BG levels. After trimethoprim–sulphamethoxazole-
associated haematotoxicity necessitated a treatment change to clindamycin–primaquine (Clinda/Prima), the patient’s condition deteriorated clini-
cally, radiologically and microbiologically. At the same time, BG and lactate dehydrogenase (LDH) levels increased by 644% and 26%, respectively.
Decreasing BG levels were observed when therapy was changed again to trimethoprim–sulphamethoxazole and later to atovaquone. To rule out
clindamycin as a confounding factor, clindamycin solutions were tested but did not contain substantial amounts of BG (data not shown).
(b) Patient with a pulmonary co-infection (P. jirovecii and cytomegalovirus (CMV)). Despite treatment with trimethoprim–sulphamethoxazole and
ganciclovir, the patient’s condition deteriorated within the ﬁrst 12 days. Decreasing BG levels and increasing CMV copy numbers in the blood
suggested trimethoprim–sulphamethoxazole efﬁcacy and ganciclovir treatment failure. Therefore, trimethoprim–sulphamethoxazole therapy was
continued, and ganciclovir was replaced by foscavir. The patient responded well to the new regimen, and the further clinical course was unevent-
ful. Repeated P. jirovecii immunoﬂuorescence (PJ-IFT) stainings of bronchoalveolar lavage ﬂuids were negative, conﬁrming trimethoprim–sulpha-
methoxazole efﬁcacy. The intermittent BG peaks might be the result of Octagam administration (see text). (c, d) Both patients had initially
decreasing BG levels that paralleled their clinical improvement. However, in both cases, BG levels started to increase strongly from day 10. This
increase did not correlate with any clinical deterioration or suspicion of treatment failure. At about the same time, one of them developed oral
candidiasis and the other pancreatitis. Theoretically, BG from Candida could pass through the oral or gastrointestinal mucous membrane and
enter the bloodstream. However, the data that exist so far do not support superﬁcial or oral candidiasis as a source of systemic BG [4], and
nothing is known about false-positive BG levels in patients with pancreatitis. The change of PJP therapy in (d) took place because of trimetho-
prim–sulphamethoxazole toxicity. SpO2, saturation of peripheral oxygen; Stop O2, cessation of supportive oxygen therapy.
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of the following criteria were met: existing immunosuppres-
sion, fever, dyspnoea, cough, elevated LDH, and hypoxia.
All serum samples were examined for the presence of BG
by use of the Fungitell assay (Associates of Cape Cod, East
Falmouth, MA, USA). The test was performed according to
the manufacturer’s recommendations. In a recent study, we
identiﬁed 85 pg/mL as the optimal BG cut-off for the diagno-
sis of PJP [3].
Sera from 18 patients were included in the study (seven
patients with human immunodeﬁciency virus infection, three
after kidney transplantation, one stem cell transplant recipi-
ent, and seven patients under immunosuppression for Hodg-
kin’s lymphoma, non-Hodgkin’s lymphoma (two patients),
glioblastoma multiforme, myasthenia gravis, idiopathic throm-
bocytopenic purpura and pemphigus vulgaris). The median age
of the patients was 53 years (interquartile range (IQR)
45–58), the median length of hospitalization was 32 days
(IQR 23–49), and the median length of PJP therapy was
21 days (IQR 19–31). All 18 patients received high-dose
trimethoprim–sulphamethoxazole as ﬁrst-line therapy. A
change to second-line therapy with clindamycin–primaquine
was necessary in seven patients, and two of them received
atovaquone as third-line therapy. A median of seven follow-up
sera (IQR 6–9) per patient were tested. The median BG
concentration at diagnosis and the median maximum BG con-
centration during follow-up (BGMAX) were 2353 pg/mL (IQR
790–3710) and 2894 pg/mL (IQR 1166–23 490), respectively.
To compare the consecutive BG levels of each case with
the clinical course, we ﬁrst grouped the patients according
to the pattern of their BG kinetics: BG kinetics group 1
comprised all patients with constantly decreasing BG levels
(n = 8); BG kinetics group 2 showed an increase in BG levels
(n = 6); and BG kinetics group 3 had complex BG kinetics
with one or more episodes of decreasing and increasing BG
concentrations (n = 4).
Simultaneously, the clinical course and the treatment
response were independently analysed by an infectious dis-
ease specialist, using laboratory results (procalcitonin, C-
reactive protein, leukocyte count, and LDH), body tempera-
ture, radiological images, parameters of respiration and artiﬁ-
cial ventilation (arterial partial pressure of oxygen, saturation
of peripheral oxygen, fraction of inspired oxygen, positive
end-expiratory pressure, and mode of ventilation), and the
results of subsequent microbiological examination of BALFs.
On the basis of the clinical evaluation, each patient was
assigned to one of the following three clinical groups:
patients with mild PJP and successful ﬁrst-line therapy
(n = 10); patients with severe PJP and successful ﬁrst-line
therapy (n = 4); and patients with clinically suspected treat-
ment failure or fatal outcome (n = 4). Patients were consid-
ered to have had a severe course of the disease if there was
no clinical improvement within the ﬁrst 10 days of therapy, if
treatment in an intensive-care unit or mechanical ventilation
was necessary and if high-dose/intravenous therapy needed
to be continued after 21 days.
BG kinetics and clinical group were then compared for
each patient. Seven (88%) members of BG kinetics group 1
(constantly decreasing BG levels; two examples in Fig. 1a,b)
were categorized as having mild PJP with successful ﬁrst-line
therapy, whereas one patient with severe pre-existing lung
disease died 18 days after the start of trimethoprim–sulpha-
methoxazole treatment. Although no clinical or radiological
improvement was seen in this patient, consecutive BALFs did
not show P. jirovecii cysts after day 12. This would suggest
that his death was not directly P. jirovecii-associated, and that
the decreasing BG levels probably reﬂected declining P. ji-
rovecii cyst numbers.
Of the six members of BG kinetics group 2 (increasing
BG levels; two examples in Fig. 1c,d), two had mild PJP with
successful ﬁrst-line therapy, one had severe PJP with success-
ful ﬁrst-line therapy, one had suspected treatment failure,
and two patients died. Therefore, increasing BG levels and
clinical deterioration were associated in only 50% of cases.
The remaining patients in this group responded well to tri-
methoprim–sulphamethoxazole therapy, although BG levels
would have implied treatment failure.
BG kinetics group 3 (complex BG course, Fig. 2a–d) con-
sisted of four patients. Three of them had severe PJP and
one had mild PJP. All patients responded well to ﬁrst-line
therapy. However, the BG course was consistent with the
clinical course in only 50% of cases.
Altogether, our results indicated an overall correlation of
BG kinetics with clinical course in 61% of patients. Separate
analysis of the different subgroups showed that decreasing
BG levels were associated with a favourable outcome in 88%
of cases. In contrast, increasing BG levels reﬂected death or
treatment failure in only 44% of patients, whereas the
remaining 56% responded well to PJP therapy.
One concern raised by some of the recent studies investi-
gating the performance of BG measurement for the diagnosis
of invasive fungal infections was the poor positive predictive
value of this test [7,8]. The results of our study seem to sup-
port this observation. Several factors are known to cause
false-positive BG results, including the administration of
intravenous immunoglobulins (IVIGs) or albumin, and hae-
modialysis with certain cellulose membranes [9–11]. In our
study, a common feature of most patients with a BG
increase during follow-up was the extremely high BG peak
level (BGMAX = 25 969 pg/mL and IQR 15 070–33 540 for
patients with increasing BG levels vs. BGMAX = 1488 pg/mL
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and IQR 599–2552 for patients with decreasing BG levels).
In addition, peak levels were reached as late as 18 days
(median, IQR 13–23) after initiation of ﬁrst-line therapy. In
our opinion, it is highly questionable whether BG levels
above 5000 pg/mL developing after more than 10 days of
therapy are a direct result of P. jirovecii proliferation. To ﬁnd
another explanation for the high BG levels, we reviewed the
charts of these patients (n = 10) for confounding factors of
BG measurement. Four of them received IVIGs, four
received albumin, and two were on haemodialysis. We then
tested sera of non-study patients immediately before and
20 min after administration of various IVIGs (n = 28) and
albumin (n = 5), as well as before and after haemodialysis
(n = 15). Whereas haemodialysis with polysulphone and cel-
lulose triacetate membranes did not have a signiﬁcant inﬂu-
ence, the administration of IVIGs or albumin resulted in a
considerable increase in serum BG (mean increase per
10 g ± standard deviation: Intractect, 1632 ± 60 pg/mL; Privi-
gen, 300 ± 91 pg/mL; Octagam, 194 ± 27 pg/mL; Kiovig,
119 ± 22 pg/mL; albumin 20%, 156 ± 32 pg/mL). Perhaps
with the exception of Intratect, the IVIG-mediated or albu-
min-mediated BG increase was not strong enough to explain
the extraordinarily high BG levels observed in some patients.
However, none of our patients received Intratect. On the
basis of these results, it may be hypothesized that there are
as yet unknown factors inﬂuencing BG measurement, and
that the risk of false-positive BG results increases with the
complexity of treatment and the length of hospitalization.
A limitation of our study is the small number of patients
(n = 18). Therefore, further work is clearly necessary to
conﬁrm and ﬁne-tune our results in larger series.
In summary, decreasing BG levels show a good correlation
(88%) with a favourable treatment response. This may assist
in deciding whether to continue ﬁrst-line therapy in cases of
missing clinical improvement. Under special circumstances,
consecutive BG measurements might be suitable for the
identiﬁcation of treatment failure. However, the overall cor-
relation of increasing BG levels with an adverse outcome is
poor (44%), and its usefulness for follow-up in severe PJP is
very limited.
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